W
WAVEMAN · COMPANY
VRTX · Vertex Pharmaceuticals Inc / Ma
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475
← ALL COMPANIES

VRTX

VERTEX PHARMACEUTICALS INC / MA
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0000875320
FORM 144 · 6☆ WATCH
INSIDER NET · 180D
-$14.9M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
0
13F, latest reported quarter
REVENUE GROWTH
+8.9%
XBRL, annual
NET MARGIN
32.9%
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$14.9M over 180 days
-$4.6M over 90 days
below 87% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
fewer than five institutions report holding it
REVENUE
+8.9% year over year
more than 60% of Pharma & Biotech
MARGIN
32.9% net margin
more than 93% of Pharma & Biotech
BUYBACKS
$806.4M repurchased, FY to 2026-06-30
more than 93% of Pharma & Biotech
SHORT
no short interest reported
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$14.9M across 6 people in 180 days.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +38.8%
+38.8%12M
-6%+9%+24%+39%2025-092025-102025-122026-032026-052026-072026-09 2025-11-14 · LEIDEN JEFFREY M sold $14.2M2025-11-14 · LEIDEN JEFFREY M sold $9.4M2026-02-19 · Sachdev Amit sold $9.2M2025-11-13 · LEIDEN JEFFREY M sold $8.2M2026-02-27 · Kewalramani Reshma sold $7.7M2025-12-03 · LEIDEN JEFFREY M sold $7.1M2026-02-19 · Sachdev Amit sold $5.5M2026-02-19 · Sachdev Amit sold $4.8M2025-12-03 · LEIDEN JEFFREY M sold $4.7M2026-01-06 · WAGNER CHARLES F JR sold $4.4M2025-12-03 · LEIDEN JEFFREY M sold $3.5M2026-02-19 · Sachdev Amit sold $3.4M2025-12-03 · WAGNER CHARLES F JR sold $3.2M2025-12-03 · WAGNER CHARLES F JR sold $3.2M2026-05-12 · Bozic Carmen sold $3.1M2026-02-27 · Kewalramani Reshma sold $3.0M2025-12-03 · LEIDEN JEFFREY M sold $2.6M2025-12-03 · LEIDEN JEFFREY M sold $2.6M2026-01-07 · Tatsis Ourania sold $2.1M2025-12-03 · Tatsis Ourania sold $2.0M2026-02-19 · Sachdev Amit sold $2.0M2025-12-03 · LEIDEN JEFFREY M sold $2.0M2025-12-03 · LEIDEN JEFFREY M sold $1.9M2026-06-15 · Bozic Carmen sold $1.8M2026-02-27 · Kewalramani Reshma sold $1.7M2026-02-27 · Kewalramani Reshma sold $1.6M2026-02-27 · Kewalramani Reshma sold $1.3M2026-03-11 · McKechnie Duncan sold $1.3M2026-02-19 · Sachdev Amit sold $1.3M2026-02-27 · Kewalramani Reshma sold $1.2M2026-02-27 · Kewalramani Reshma sold $1.2M2026-02-25 · McKechnie Duncan sold $1.2M2026-02-17 · Biller Jonathan sold $1.2M2026-02-17 · Bunnage Mark E. sold $1.2M2026-02-25 · McKechnie Duncan sold $1.2M2026-03-04 · McKechnie Duncan sold $1.2M2026-03-13 · Bozic Carmen sold $1.1M2026-02-27 · Bozic Carmen sold $1.1M2025-12-03 · LEIDEN JEFFREY M sold $1.1M2025-11-17 · Atkinson Edward Morrow III sold $1.1M2026-03-27 · Bozic Carmen sold $1.1M2025-12-03 · LEIDEN JEFFREY M sold $1.0M2026-08-27 · Bruce I. Sachs filed to sell $662.5K2026-07-02 · McKechnie Duncan filed to sell $799.8K2026-07-02 · Tatsis Ourania filed to sell $787.5K2026-07-01 · Liu Joy filed to sell $416.2K2026-06-26 · Bozic Carmen filed to sell $287.6K2026-06-18 · Bozic Carmen filed to sell $471.4K
INSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $14.9M sold by insiders over 180 days, $3.4M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNANUVLINSM
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, VERTEX PHARMACEUTICALS INC / MA insiders sold a net $14.9M of stock across 602 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER
FILED
SHARES
VALUE
McKechnie Duncan
EVP, Chief Commercial Officer
SELL
2026-07-02
1,541.0
$799.8K
Tatsis Ourania
EVP, Chief Reg. & Quality Off.
SELL
2026-07-02
1,500.0
$787.5K
Liu Joy
EVP and Chief Legal Officer
SELL
2026-07-01
828.0
$416.2K
Bozic Carmen
EVP and CMO
SELL
2026-06-26
596.0
$287.6K
Bozic Carmen
EVP and CMO
SELL
2026-06-18
1,020.0
$471.4K
602 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 597 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported

no 13F holders found for this ticker

SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
Bruce I. Sachs
FILED 2026-08-27
$662.5K
McKechnie Duncan
FILED 2026-07-02
$799.8K
Tatsis Ourania
FILED 2026-07-02
$787.5K
Liu Joy
FILED 2026-07-01
$416.2K
Bozic Carmen
FILED 2026-06-26
$287.6K
Executive pay vs shareholder return · Reshma Kewalramani
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2025
$21.1M
$38.2M
$7.7M
+92%
+25%
2024
$21.5M
$43.6M
$8.1M
+70%
-7%
2023
$20.6M
$44.2M
$7.4M
+72%
-6%
2022
$15.9M
$29.5M
$9.0M
+22%
-10%
2021
$15.2M
$18.3M
$7.2M
-7%
+0%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$12.0B$11.0B$9.9B$8.9B
OPERATING INCOME$4.2B$-232.9M$3.8B$4.3B
NET INCOME$4.0B$-535.6M$3.6B$3.3B
EPS (DILUTED)15.32-2.0813.8912.82
OPERATING CASH FLOW$3.6B$-492.6M$3.5B$4.1B
CASH$5.1B$4.6B$10.4B$10.5B
BUYBACKS$2.0B$1.2B$427.6M$0
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-04 ALL SYSTEMS LIVE FOR MACHINES →